Can a Hormone-Radiation combo save erectile function in prostate cancer?
NCT ID NCT07302451
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether combining a 12-month course of the hormone therapy Relugolix with precise, image-guided radiation can help men with intermediate-risk prostate cancer recover erectile function. Fifty men will receive the treatment and complete questionnaires about sexual function, quality of life, and financial impact. The main goal is to see if at least 70% of participants regain meaningful erectile function within six months of stopping hormone therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Relugolix (hormone therapy) and stereotactic body radiotherapy (SBRT)
What this could lead to
If successful, this approach could help men with intermediate-risk prostate cancer recover erectile function and maintain quality of life after treatment.
What could go wrong
This is a small, early-phase study with only 50 participants, so results may not apply to all patients. The hormone therapy can cause side effects like hot flashes and fatigue, and erectile recovery is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale - Napoli
Naples, 80131, Italy